Anti–TROP-2 antibody–drug conjugate that binds TROP-2 on tumor cells, is internalized, and releases a cytotoxic payload to kill TROP-2–expressing cancer cells.
An anti–TROP-2 IgG1 antibody–drug conjugate that binds TROP-2 on tumor cells, is internalized, and via a cleavable linker releases the exatecan-derived topoisomerase I inhibitor SHR9265, inhibiting DNA replication and inducing cell-cycle arrest and apoptosis in TROP-2–expressing cancer cells.
YES
DIRECT
An anti–TROP-2 ADC binds TROP-2, is internalized, and releases an exatecan-derived topoisomerase I inhibitor (SHR9265) that inhibits DNA replication, causing cell-cycle arrest and apoptosis in TROP-2–expressing cells.
Anti–TROP-2 antibody–drug conjugate that binds TROP-2 on tumor cells, is internalized, and releases a cytotoxic payload to kill TROP-2–expressing cancer cells.
An anti–TROP-2 IgG1 antibody–drug conjugate that binds TROP-2 on tumor cells, is internalized, and via a cleavable linker releases the exatecan-derived topoisomerase I inhibitor SHR9265, inhibiting DNA replication and inducing cell-cycle arrest and apoptosis in TROP-2–expressing cancer cells.
NO
INDIRECT
The ADC binds TROP-2 on tumor cells, is internalized, and releases a topoisomerase I–inhibiting payload that induces DNA damage, cell-cycle arrest, and apoptosis; it does not directly target DNA topoisomerase I–expressing cells for binding.
An intravenous CD70-targeted antibody-drug conjugate (ADC) comprising an anti-CD70 monoclonal antibody linked to a topoisomerase I inhibitor payload; binds CD70 on tumor cells, is internalized, and releases the cytotoxic payload to induce DNA damage and tumor cell death.
CD70-targeted monoclonal antibody linked to a topoisomerase I inhibitor; binds CD70 on tumor cells, is internalized, and releases the cytotoxic payload to inhibit topoisomerase I, causing DNA damage and tumor cell death.
YES
DIRECT
The CD70-targeted ADC binds CD70 on CD70+ cells, is internalized, and releases a topoisomerase I inhibitor that induces DNA damage, leading to apoptosis of the target-expressing cells.
Investigational bispecific antibody immunotherapy that engages two antitumor targets to enhance immune-mediated tumor killing.
Bispecific antibody designed to simultaneously bind a tumor-associated antigen and CD3 on T cells, recruiting and activating cytotoxic T cells to form an immune synapse and drive targeted tumor cell lysis.
NO
INDIRECT
The bispecific binds CD3 on T cells to recruit/activate them and bridge them to tumor-antigen–positive cells; T cells then kill the tumor cells via perforin/granzyme, not the CD3+ cells.
An intravenous CD70-targeted antibody-drug conjugate (ADC) comprising an anti-CD70 monoclonal antibody linked to a topoisomerase I inhibitor payload; binds CD70 on tumor cells, is internalized, and releases the cytotoxic payload to induce DNA damage and tumor cell death.
CD70-targeted monoclonal antibody linked to a topoisomerase I inhibitor; binds CD70 on tumor cells, is internalized, and releases the cytotoxic payload to inhibit topoisomerase I, causing DNA damage and tumor cell death.
NO
INDIRECT
This ADC binds CD70 (not topoisomerase I), is internalized, and releases a topoisomerase I–inhibiting payload that causes DNA damage and kills CD70+ cells; topoisomerase I expression alone does not confer targeting.